1. 166Ho-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma: results of two phase 1/2 trials
by Sergio Giralt, William Bensinger, Mark Goodman, Donald Podoloff, Janet Eary, Richard Wendt, Raymond Alexanian, Donna Weber, David Maloney, Leona Holmberg, Joseph Rajandran, Hazel Breitz, Richard Ghalie, and Richard Champlin
Blood
Volume 102(7):
October 1, 2003
©2003 by American Society of Hematology

2. Patient survival.
Patient survival. Symbols represent time points at which observations were made. Top panel: survival of all patients (n = 82) according to patient response to transplant. ○ indicates complete response; ⋄, stable disease; □, partial response; and no symbols, progressive disease. Bottom panel: survival of patients according to actual dose to the marrow. ○ indicates patients who received an actual dose of 30 Gy or less to the marrow (n = 37); ⋄, patients who received more than 30 Gy to the marrow (n = 45).
Sergio Giralt et al. Blood 2003;102:
©2003 by American Society of Hematology